#fibrosis

The burden of viral and nonviral liver disease remains high even in the setting of hepatitis C microelimination.

People with advanced fibrosis—not just cirrhosis—were at greater risk for hepatocellular carcinoma.

However, people with liver cirrhosis remain at risk and should continue screening even after being cured.

Developing treatments for fatty liver disease has proved challenging, and there are currently no approved medications.

The best-performing combo, firsocostat and cilofexor, showed benefits despite missing the main study endpoint.

The regulatory agency requested further data to show whether its benefits outweigh its risks.

Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.

Additionally, among those with non-alcoholic fatty liver disease, indicators of liver fibrosis are associated with cancer.